Molecular basis of cardioprotection by erythropoietin

Current Molecular Pharmacology

Volumn 2, Issue 1, 2009, Pages 56-69

  Burger, D ^a   Xenocostas, A ^a,b   Feng, Q P ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Angiogenesis; Apoptosis; Cardioprotection; Erythropoietin; Ischemia and reperfusion; Myocardial infarction; Nitric oxide; Signal transduction

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; PROTEIN KINASE B; PROTEIN KINASE C; CARDIOTONIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; NITRIC OXIDE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDITIS; DRUG ACTIVITY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; METABOLISM; MOUSE; RAT; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOTONIC AGENTS; ERYTHROPOIETIN; GLYCOGEN SYNTHASE KINASE 3; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 66749173169     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467210902010056     Document Type: Article

References (194)

1. Jacobson, L. O.; Goldwasser, E.; Fried, W.; Plzak, L. F. Studies on erythro poiesis. VII. The role of the kidney in the production of erythropoietin. Trans. Assoc. Am. Physicians 1957, 70, 305-317.
2. Kuratowska, Z.; Lewartowski, B.; Michalak, E. Studies on the production of erythropoietin by isolated perfused organs. Blood 1961, 18, 527-534.
3. Koury, S. T.; Bondurant, M. C.; Koury, M. J. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988, 71, 524-527.
4. Bonsdorff, E.; Jalavisto, E. A humoral mechanism in anoxic erythrocytosis. Acta Physiol. Scand. 1948, 16, 150-170.
5. Carnot, P.; Deflandre, C. Sur l'activité hémopoiétique du sérum au cours de la régénération du sang. R Acad. Sci. Paris 1906, 143, 432-435.
6. Erslev, A. J. Effect of erythropoietin on the uptake and utilization of iron by bone marrow cells in vitro. Proc. Soc. Exp. Biol. Med. 1962, 110, 615-620.
7. Gurney, C. W.; Wackman, N.; Filmanowicz, E. Studies on erythropoiesis. XVII. Some quantitative aspects of the erythropoietic response to erythropoietin. Blood 1961, 17, 531-546.
8. Filmanowicz, E.; Gurney, C. W. Studies on erythropoiesis. XVI. Response to a single dose of erythropoietin in polycythemic mouse. J. Lab. Clin. Med. 1961, 57, 65-72.
9. Koury, M. J.; Bondurant, M. C. The mechanism of erythropoietin action. Am. J. Kidney Dis. 1991, 18, 20-23.
10. Koury, M. J.; Bondurant, M. C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990, 248, 378-381.
11. Koury, M. J.; Bondurant, M. C. Control of red cell production: the roles of programmed cell death (apoptosis) and erythropoietin. Transfusion 1990, 30, 673-674.
12. Wu, H.; Liu, X.; Jaenisch, R.; Lodish, H. F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995, 83, 59-67.
13. Lin, C. S.; Lim, S. K.; D'Agati, V.; Costantini, F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996, 10, 154-164.
14. Suzuki, N.; Ohneda, O.; Takahashi, S.; Higuchi, M.; Mukai, H. Y.; Nakahata, T.; Imagawa, S.; Yamamoto, M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002, 100, 2279-2288.
15. Krantz, S. B. Erythropoietin. Blood 1991, 77, 419-434.
16. Ng, T.; Marx, G.; Littlewood, T.; Macdougall, I. Recombinant erythropoietin in clinical practice. Postgrad. Med. J. 2003, 79, 367-376.
17. Marti, H. H.; Wenger, R. H.; Rivas, L. A.; Straumann, U.; Digicaylioglu, M.; Henn, V.; Yonekawa, Y.; Bauer, C.; Gassmann, M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 1996, 8, 666-676.
18. Anagnostou, A.; Liu, Z.; Steiner, M.; Chin, K.; Lee, E. S.; Kessimian, N.; Noguchi, C. T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3974-3978.
19. Mengozzi, M.; Latini, R.; Salio, M.; Sfacteria, A.; Piedimonte, G.; Gerwien, J. G.; Leist, M.; Siren, A. L.; Ghezzi, P.; Chimenti, S. Increased erythropoietin production after myocardial infarction in mice. Heart 2006, 92, 838-839.
20. Cai, Z.; Manalo, D. J.; Wei, G.; Rodriguez, E. R.; Fox-Talbot, K.; Lu, H.; Zweier, J. L.; Semenza, G. L. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003, 108, 79-85.
21. Wen, T. C.; Sadamoto, Y.; Tanaka, J.; Zhu, P. X.; Nakata, K.; Ma, Y. J.; Hata, R.; Sakanaka, M. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J. Neurosci. Res. 2002, 67, 795-803.
22. Sakanaka, M.; Wen, T. C.; Matsuda, S.; Masuda, S.; Morishita, E.; Nagao, M.; Sasaki, R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl. Acad. Sci. USA 1998, 95, 4635-4640.
23. Bernaudin, M.; Marti, H. H.; Roussel, S.; Divoux, D.; Nouvelot, A.; MacKenzie, E. T.; Petit, E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 1999, 19, 643-651.
24. Grimm, C.; Wenzel, A.; Acar, N.; Keller, S.; Seeliger, M.; Gassmann, M. Hypoxic preconditioning and erythropoietin protect retinal neurons from degeneration. Adv. Exp. Med. Biol. 2006, 588, 119-131.
25. Grimm, C.; Hermann, D. M.; Bogdanova, A.; Hotop, S.; Kilic, U.; Wenzel, A.; Kilic, E.; Gassmann, M. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell Dev. Biol. 2005, 16, 531-538.
26. Grimm, C.; Wenzel, A.; Stanescu, D.; Samardzija, M.; Hotop, S.; Groszer, M.; Naash, M.; Gassmann, M.; Reme, C. Constitutive overexpression of human erythropoietin protects the mouse retina against induced but not inherited retinal degeneration. J. Neurosci. 2004, 24, 5651-5658.
27. Chong, Z. Z.; Li, F.; Maiese, K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr. Neurovasc. Res. 2005, 2, 387-399.
28. Vesey, D. A.; Cheung, C.; Pat, B.; Endre, Z.; Gobe, G.; Johnson, D. W. Erythropoietin protects against ischaemic acute renal injury. Nephrol. Dial. Transplant. 2004, 19, 348-355.
29. Johnson, D. W.; Pat, B.; Vesey, D. A.; Guan, Z.; Endre, Z.; Gobe, G. C. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006, 69, 1806-1813.
30. Patel, N. S.; Sharples, E. J.; Cuzzocrea, S.; Chatterjee, P. K.; Britti, D.; Yaqoob, M. M.; Thiemermann, C. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004, 66, 983-989.
31. Sharples, E. J.; Patel, N.; Brown, P.; Stewart, K.; Mota-Philipe, H.; Sheaff, M.; Kieswich, J.; Allen, D.; Harwood, S.; Raftery, M.; Thiemermann, C.; Yaqoob, M. M. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 2004, 15, 2115-2124.
32. Xue, Y. Q.; Zhao, L. R.; Guo, W. P.; Duan, W. M. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 2007, 146, 1245-1258.
33. Sepodes, B.; Maio, R.; Pinto, R.; Sharples, E.; Oliveira, P.; McDonald, M.; Yaqoob, M.; Thiemermann, C.; Mota-Filipe, H. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl. Int. 2006, 19, 919-926.
34. Calvillo, L.; Latini, R.; Kajstura, J.; Leri, A.; Anversa, P.; Ghezzi, P.; Salio, M.; Cerami, A.; Brines, M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. USA 2003, 100, 4802-4806.
35. Cai, Z.; Semenza, G. L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004, 109, 2050-2053.
36. Fisher, J. W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 2003, 228, 1-14.
37. Witthuhn, B. A.; Quelle, F. W.; Silvennoinen, O.; Yi, T.; Tang, B.; Miura, O.; Ihle, J. N. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74, 227-236.
38. Miura, O.; Nakamura, N.; Quelle, F. W.; Witthuhn, B. A.; Ihle, J. N.; Aoki, N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood 1994, 84, 1501-1507.
39. Livnah, O.; Stura, E. A.; Middleton, S. A.; Johnson, D. L.; Jolliffe, L. K.; Wilson, I. A. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283, 987-990.
40. He, T. C.; Zhuang, H.; Jiang, N.; Waterfield, M. D.; Wojchowski, D. M. Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain. Blood 1993, 82, 3530-3538.
41. Miura, Y.; Miura, O.; Ihle, J. N.; Aoki, N. Activation of the mitogenactivated protein kinase pathway by the erythropoietin receptor. J. Biol. Chem. 1994, 269, 29962-29969.
42. Ren, H. Y.; Komatsu, N.; Shimizu, R.; Okada, K.; Miura, Y. Erythropoietin induces tyrosine phosphorylation and activation of phospholipase C-gamma 1 in a human erythropoietin-dependent cell line. J. Biol. Chem. 1994, 269, 19633-19638.
43. Jubinsky, P. T.; Krijanovski, O. I.; Nathan, D. G.; Tavernier, J.; Sieff, C. A. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997, 90, 1867-1873.
44. Jubinsky, P. T.; Nathan, D. G.; Wilson, D. J.; Sieff, C. A. A low-affinity human granulocyte-macrophage colony-stimulating factor/murine erythropoietin hybrid receptor functions in murine cell lines. Blood 1993, 81, 587-591.
45. Scott, C. L.; Robb, L.; Papaevangeliou, B.; Mansfield, R.; Nicola, N. A.; Begley, C. G. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood 2000, 96, 1588-1590.
46. Brines, M.; Grasso, G.; Fiordaliso, F.; Sfacteria, A.; Ghezzi, P.; Fratelli, M.; Latini, R.; Xie, Q. W.; Smart, J.; Su-Rick, C. J.; Pobre, E.; Diaz, D.; Gomez, D.; Hand, C.; Coleman, T.; Cerami, A. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. USA 2004, 101, 14907-14912.
47. Leist, M.; Ghezzi, P.; Grasso, G.; Bianchi, R.; Villa, P.; Fratelli, M.; Savino, C.; Bianchi, M.; Nielsen, J.; Gerwien, J.; Kallunki, P.; Larsen, A. K.; Helboe, L.; Christensen, S.; Pedersen, L. O.; Nielsen, M.; Torup, L.; Sager, T.; Sfacteria, A.; Erbayraktar, S.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Cerami-Hand, C.; Xie, Q. W.; Coleman, T.; Cerami, A.; Brines, M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305, 239-242.
48. Moon, C.; Krawczyk, M.; Paik, D.; Coleman, T.; Brines, M.; Juhaszova, M.; Sollott, S. J.; Lakatta, E. G.; Talan, M. I. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther. 2006, 316, 999-1005.
49. Erbayraktar, S.; Grasso, G.; Sfacteria, A.; Xie, Q. W.; Coleman, T.; Kreilgaard, M.; Torup, L.; Sager, T.; Erbayraktar, Z.; Gokmen, N.; Yilmaz, O.; Ghezzi, P.; Villa, P.; Fratelli, M.; Casagrande, S.; Leist, M.; Helboe, L.; Gerwein, J.; Christensen, S.; Geist, M. A.; Pedersen, L. O.; Cerami-Hand, C.; Wuerth, J. P.; Cerami, A.; Brines, M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. USA 2003, 100, 6741-6746.
50. Lekas, M.; Kutryk, M. J.; Latter, D. A.; Stewart, D. J. Therapeutic neovascularization for ischemic heart disease. Can. J. Cardiol. 2004, 20(Suppl. B), 49B-57B.
51. Kumamoto, H.; Okamoto, H.; Watanabe, M.; Onozuka, H.; Yoneya, K.; Nakagawa, I.; Chiba, S.; Watanabe, S.; Mikami, T.; Abe, K.; Kitabatake, A. Beneficial effect of myocardial angiogenesis on cardiac remodeling process by amlodipine and MCI-154. Am. J. Physiol. 1999, 276, H1117-H1123.
52. Friehs, I.; Margossian, R. E.; Moran, A. M.; Cao-Danh, H.; Moses, M. A.; del Nido, P. J. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res. Cardiol. 2006, 101, 204-213.
53. Friehs, I.; Moran, A. M.; Stamm, C.; Choi, Y. H.; Cowan, D. B.; McGowan, F. X.; del Nido, P. J. Promoting angiogenesis protects severely hypertrophied hearts from ischemic injury. Ann. Thorac. Surg. 2004, 77, 2004-2010; discussion 2011.
54. Fukuda, S.; Kaga, S.; Zhan, L.; Bagchi, D.; Das, D. K.; Bertelli, A.; Maulik, N. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 2006, 44, 43-49.
55. Chen, L. L.; Yin, H.; Huang, J. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc. Pathol. 2007, 16, 221-230.
56. Lu, H.; Xu, X.; Zhang, M.; Cao, R.; Brakenhielm, E.; Li, C.; Lin, H.; Yao, G.; Sun, H.; Qi, L.; Tang, M.; Dai, H.; Zhang, Y.; Su, R.; Bi, Y.; Cao, Y. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc. Natl. Acad. Sci. USA 2007, 104, 12140-12145.
57. Schumacher, B.; von Specht, B. U.; Haberstroh, J.; Pecher, P. The stimulation of neo-angiogenesis in the ischemic heart by the human growth factor FGF. J. Cardiovasc. Surg. (Torino) 1998, 39, 445-453.
58. Ripa, R. S.; Wang, Y.; Jorgensen, E.; Johnsen, H. E.; Hesse, B.; Kastrup, J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur. Heart J. 2006, 27, 1785-1792.
59. Mehrabi, M. R.; Serbecic, N.; Tamaddon, F.; Pacher, R.; Horvath, R.; Mall, G.; Glogar, H. D. Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed. Pharmacother. 2003, 57, 173-178.
60. Losordo, D. W.; Vale, P. R.; Symes, J. F.; Dunnington, C. H.; Esakof, D. D.; Maysky, M.; Ashare, A. B.; Lathi, K.; Isner, J. M. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998, 98, 2800-2804.
61. Vale, P. R.; Losordo, D. W.; Milliken, C. E.; Maysky, M.; Esakof, D. D.; Symes, J. F.; Isner, J. M. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000, 102, 965-974.
62. Anagnostou, A.; Lee, E. S.; Kessimian, N.; Levinson, R.; Steiner, M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 1990, 87, 5978-5982.
63. Kertesz, N.; Wu, J.; Chen, T. H.; Sucov, H. M.; Wu, H. The role of erythropoietin in regulating angiogenesis. Dev. Biol. 2004, 276, 101-110.
64. Carlini, R. G.; Reyes, A. A.; Rothstein, M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995, 47, 740-745.
65. Carlini, R. G.; Alonzo, E. J.; Dominguez, J.; Blanca, I.; Weisinger, J. R.; Rothstein, M.; Bellorin-Font, E. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int. 1999, 55, 546-553.
66. Ribatti, D.; Presta, M.; Vacca, A.; Ria, R.; Giuliani, R.; Dell'Era, P.; Nico, B.; Roncali, L.; Dammacco, F. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93, 2627-2636.
67. Pedram, A.; Razandi, M.; Hu, R. M.; Levin, E. R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 1997, 272, 17097-17103.
68. Valdembri, D.; Serini, G.; Vacca, A.; Ribatti, D.; Bussolino, F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 2002, 16, 225-227.
69. Itoh, T.; Tanioka, M.; Yoshida, H.; Yoshioka, T.; Nishimoto, H.; Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58, 1048-1051.
70. Jaquet, K.; Krause, K.; Tawakol-Khodai, M.; Geidel, S.; Kuck, K. H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 2002, 64, 326-333.
71. Nakano, M.; Satoh, K.; Fukumoto, Y.; Ito, Y.; Kagaya, Y.; Ishii, N.; Sugamura, K.; Shimokawa, H. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ. Res. 2007, 100, 662-669.
72. van der Meer, P.; Lipsic, E.; Henning, R. H.; Boddeus, K.; van der Velden, J.; Voors, A. A.; van Veldhuisen, D. J.; van Gilst, W. H.; Schoemaker, R. G. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol. 2005, 46, 125-133.
73. Nishiya, D.; Omura, T.; Shimada, K.; Matsumoto, R.; Kusuyama, T.; Enomoto, S.; Iwao, H.; Takeuchi, K.; Yoshikawa, J.; Yoshiyama, M. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J. Pharmacol. Sci. 2006, 101, 31-39.
74. George, J.; Goldstein, E.; Abashidze, A.; Wexler, D.; Hamed, S.; Shmilovich, H.; Deutsch, V.; Miller, H.; Keren, G.; Roth, A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc. Res. 2005, 68, 299-306.
75. Westenbrink, B. D.; Lipsic, E.; van der Meer, P.; van der Harst, P.; Oeseburg, H.; Du Marchie Sarvaas, G. J.; Koster, J.; Voors, A. A.; van Veldhuisen, D. J.; van Gilst, W. H.; Schoemaker, R. G. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 2007, 28, 2018-2027.
76. Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A. M.; Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102, 1340-1346.
77. Bahlmann, F. H.; De Groot, K.; Spandau, J. M.; Landry, A. L.; Hertel, B.; Duckert, T.; Boehm, S. M.; Menne, J.; Haller, H.; Fliser, D. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103, 921-926.
78. Hamed, S.; Barshack, I.; Luboshits, G.; Wexler, D.; Deutsch, V.; Keren, G.; George, J. Erythropoietin improves myocardial performance in doxorubicininduced cardiomyopathy. Eur Heart J. 2006, 27, 1876-1883.
79. Zhang, D. G.; Zhang, F. M.; Zhang, Y. Q.; Zhou, F.; Gao, X.; Li, C. F.; Cao, K. J. [Erythropoietin enhances the therapy potency of autologous bone marrow stromal cells in a rat heart infarction model via phosphatidylinositol-3-kinase/Akt pathway]. Zhonghua Xin Xue Guan Bing Za Zhi 2006, 34, 912-916.
80. Zhang, D.; Zhang, F.; Zhang, Y.; Gao, X.; Li, C.; Ma, W.; Cao, K. Erythropoietin Enhances the Angiogenic Potency of Autologous Bone Marrow Stromal Cells in a Rat Model of Myocardial Infarction. Cardiology 2006, 108, 228-236.
81. Urao, N.; Okigaki, M.; Yamada, H.; Aadachi, Y.; Matsuno, K.; Matsui, A.; Matsunaga, S.; Tateishi, K.; Nomura, T.; Takahashi, T.; Tatsumi, T.; Matsubara, H. Erythropoietin-mobilized endothelial progenitors enhance reendo thelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ. Res. 2006, 98, 1405-1413.
82. Rakusan, K.; Cicutti, N.; Kolar, F. Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1407-H1414.
83. Dunst, J.; Pigorsch, S.; Hansgen, G.; Hintner, I.; Lautenschlager, C.; Becker, A. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther. Onkol. 1999, 175, 93-96.
84. Hudlicka, O.; Brown, M.; Egginton, S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 1992, 72, 369-417.
85. Ferrucci, L.; Guralnik, J. M.; Woodman, R. C.; Bandinelli, S.; Lauretani, F.; Corsi, A. M.; Chaves, P. H.; Ershler, W. B.; Longo, D. L. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am. J. Med. 2005, 118, 1288.
86. Sato, Y.; Takatsu, Y.; Kataoka, K.; Yamada, T.; Taniguchi, R.; Sasayama, S.; Matsumori, A. Serial circulating concentrations of C-reactive protein, in terleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin. Cardiol. 1999, 22, 811-813.
87. Testa, M.; Yeh, M.; Lee, P.; Fanelli, R.; Loperfido, F.; Berman, J. W.; Le Jemtel, T. H. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 1996, 28, 964-971.
88. Song, W.; Lu, X.; Feng, Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc. Res. 2000, 45, 595-602.
89. Ono, K.; Matsumori, A.; Shioi, T.; Furukawa, Y.; Sasayama, S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998, 98, 149-156.
90. Nian, M.; Lee, P.; Khaper, N.; Liu, P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 2004, 94, 1543-1553.
91. Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 2002, 91, 988-998.
92. Askari, A. T.; Brennan, M. L.; Zhou, X.; Drinko, J.; Morehead, A.; Thomas, J. D.; Topol, E. J.; Hazen, S. L.; Penn, M. S. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J. Exp. Med. 2003, 197, 615-624.
93. Saito, T.; Rodger, I. W.; Hu, F.; Robinson, R.; Huynh, T.; Giaid, A. Inhibition of COX pathway in experimental myocardial infarction. J. Mol. Cell. Cardiol. 2004, 37, 71-77.
94. Li, Y.; Takemura, G.; Okada, H.; Miyata, S.; Maruyama, R.; Li, L.; Higuchi, M.; Minatoguchi, S.; Fujiwara, T.; Fujiwara, H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc. Res. 2006, 71, 684-694.
95. Rui, T.; Feng, Q.; Lei, M.; Peng, T.; Zhang, J.; Xu, M.; Abel, E. D.; Xenocostas, A.; Kvietys, P. R. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res. 2005, 65, 719-727.
96. Liu, X.; Zhou, Z.; Feng, X.; Jia, Z.; Jin, Y.; Xu, J. Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats. Postgrad. Med. J. 2006, 82, 588-593.
97. Liu, X.; Xie, W.; Liu, P.; Duan, M.; Jia, Z.; Li, W.; Xu, J. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci. 2006, 78, 2255-2264.
98. Liu, X.; Shen, J.; Jin, Y.; Duan, M.; Xu, J. Recombinant human erythropoietin (rhEPO) preconditioning on nuclear factor-kappa B (NF-kB) activation & proinflammatory cytokines induced by myocardial ischaemiareperfusion. Indian J. Med. Res. 2006, 124, 343-354.
99. Li, L.; Takemura, G.; Li, Y.; Miyata, S.; Esaki, M.; Okada, H.; Kanamori, H.; Khai, N. C.; Maruyama, R.; Ogino, A.; Minatoguchi, S.; Fujiwara, T.; Fujiwara, H. Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. Circulation 2006, 113, 535-543.
100. Frey, N.; Katus, H. A.; Olson, E. N.; Hill, J. A. Hypertrophy of the heart: a new therapeutic target? Circulation 2004, 109, 1580-1589.
101. Messerli, F. H.; Ketelhut, R. Left ventricular hypertrophy: an independent risk factor. J. Cardiovasc. Pharmacol. 1991, 17(Suppl. 4), S59-S66; discussion S66-S67.
102. Messerli, F. H.; Schmieder, R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986, 31(Suppl. 4), 192-201.
103. Frohlich, E. D. Left ventricular hypertrophy: an independent factor of risk. Cardiovasc. Clin. 1990, 20, 85-94.
104. Frohlich, E. D. Left ventricular hypertrophy as a risk factor. Cardiol. Clin. 1986, 4, 137-144.
105. Mathew, J.; Sleight, P.; Lonn, E.; Johnstone, D.; Pogue, J.; Yi, Q.; Bosch, J.; Sussex, B.; Probstfield, J.; Yusuf, S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104, 1615-1621.
106. Okin, P. M.; Devereux, R. B.; Harris, K. E.; Jern, S.; Kjeldsen, S. E.; Lindholm, L. H.; Dahlof, B. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients. the losartan intervention for endpoint reduction in hypertension (LIFE) study. Hypertension 2007, 50, 984-990.
107. Gonzalez-Juanatey, J. R.; Pose Reino, A.; Garcia Acuna, J. M.; Castelo Fuentes, V.; Amaro Gendon, A.; Calvo Gomez, C.; Gil de la Pena, M. Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment. Eur. Heart. J. 1995, 16, 1981-1987.
108. Grandi, A. M.; Laurita, E.; Solbiati, F.; Marchesi, C.; Maresca, A. M.; Nicolini, E.; Guasti, L.; Venco, A. Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect. J. Cardiovasc. Pharmacol. 2006, 48, 207-211.
109. Grandi, A. M.; Venco, A.; Barzizza, F.; Casadei, B.; Marchesi, E.; Finardi, G. Effect of enalapril on left ventricular mass and performance in essential hypertension. Am. J. Cardiol. 1989, 63, 1093-1097.
110. Solomon, S. D.; Skali, H.; Anavekar, N. S.; Bourgoun, M.; Barvik, S.; Ghali, J. K.; Warnica, J. W.; Khrakovskaya, M.; Arnold, J. M.; Schwartz, Y.; Velazquez, E. J.; Califf, R. M.; McMurray, J. V.; Pfeffer, M. A. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005, 111, 3411-3419.
111. Solomon, S. D.; Skali, H.; Bourgoun, M.; Fang, J.; Ghali, J. K.; Martelet, M.; Wojciechowski, D.; Ansmite, B.; Skards, J.; Laks, T.; Henry, D.; Packer, M.; Pfeffer, M. A. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am. Heart J. 2005, 150, 257-262.
112. Briest, W.; Homagk, L.; Baba, H. A.; Deten, A.; Rassler, B.; Tannapfel, A.; Wagner, K. F.; Wenger, R. H.; Zimmer, H. G. Cardiac remodeling in erythropoietin-transgenic mice. Cell Physiol. Biochem. 2004, 14, 277-284.
113. Deten, A.; Shibata, J.; Scholz, D.; Briest, W.; Wagner, K. F.; Wenger, R. H.; Zimmer, H. G. Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin. Cardiovasc. Res. 2004, 61, 105-114.
114. Ruschitzka, F. T.; Wenger, R. H.; Stallmach, T.; Quaschning, T.; de Wit, C.; Wagner, K.; Labugger, R.; Kelm, M.; Noll, G.; Rulicke, T.; Shaw, S.; Lindberg, R. L.; Rodenwaldt, B.; Lutz, H.; Bauer, C.; Luscher, T. F.; Gassmann, M. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA 2000, 97, 11609-11613.
115. Swigart, R. H. Polycythemia and Right Ventricular Hypertrophy. Circ. Res. 1965, 17, 30-38.
116. Naeye, R. L. Polycythemia and hypoxia. Individual effects on heart and pulmonary arteries. Am. J. Pathol. 1967, 50, 1027-1033.
117. Cinar, Y.; Demir, G.; Pac, M.; Cinar, A. B. Effect of hematocrit on blood pressure via hyperviscosity. Am. J. Hypertens. 1999, 12, 739-743.
118. Asaumi, Y.; Kagaya, Y.; Takeda, M.; Yamaguchi, N.; Tada, H.; Ito, K.; Ohta, J.; Shiroto, T.; Shirato, K.; Minegishi, N.; Shimokawa, H. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 2007, 115, 2022-2032.
119. Paplanus, S. H.; Zbar, M. J.; Hays, J. W. Cardiac hypertrophy as a manifestation of chronic anemia. Am. J. Pathol. 1958, 34, 149-159.
120. Sanghvi, L. M.; Misra, S. N.; Banerjee, K. Cardiac enlargement in chronic severe anemia. Circulation 1960, 22, 412-418.
121. London, G. Left ventricular hypertrophy: why does it happen? Nephrol. Dial. Transplant. 2003, 18, viii2-viii6.
122. Metivier, F.; Marchais, S. J.; Guerin, A. P.; Pannier, B.; London, G. M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol. Dial. Transplant. 2000, 15(Suppl. 3), 14-18.
123. Rasic, S.; Kulenovic, I.; Zulic, I.; Haracic, A.; Cengic, M.; Uncanin, S.; Dzemidzic, J. The effect of erythropoietin treatment on left ventricular hypertrophy in haemodialysis patients. Bosn. J. Basic Med. Sci. 2003, 3, 11-15.
124. Jones, M.; Schenkel, B.; Just, J. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality. Int. J. Cardiol. 2005, 100, 253-265.
125. Massimetti, C.; Pontillo, D.; Feriozzi, S.; Costantini, S.; Capezzuto, A.; Ancarani, E. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif. 1998, 16, 317-324.
126. Cannella, G.; La Canna, G.; Sandrini, M.; Gaggiotti, M.; Nordio, G.; Movilli, E.; Mombelloni, S.; Visioli, O.; Maiorca, R. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol. Dial. Transplant. 1991, 6, 31-37.
127. Pascual, J.; Teruel, J. L.; Moya, J. L.; Liano, F.; Jimenez-Mena, M.; Ortuno, J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin. Nephrol. 1991, 35, 280-287.
128. Lezaic, V.; Vujisic, B.; Djukanovic, L.; Simin, N.; Veljovic, R. Effect of recombinant human erythropoietin therapy on left ventricular hypertrophy in hemodialysis patients. Clin. Nephrol. 1992, 38, 174-176.
129. Binley, K.; Askham, Z.; Iqball, S.; Spearman, H.; Martin, L.; de Alwis, M.; Thrasher, A. J.; Ali, R. R.; Maxwell, P. H.; Kingsman, S.; Naylor, S. Longterm reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002, 100, 2406-2413.
130. Sikole, A.; Polenakovic, M.; Spiroska, V.; Polenakovic, B.; Klinkmann, H.; Scigalla, P. Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif. Organs 2002, 26, 98-102.
131. Silverberg, D. S.; Wexler, D.; Blum, M.; Schwartz, D.; Keren, G.; Sheps, D.; Iaina, A. Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians. Isr. Med. Assoc. J. 2003, 5, 337-339.
132. Silverberg, D. S.; Wexler, D.; Blum, M.; Keren, G.; Sheps, D.; Leibovitch, E.; Brosh, D.; Laniado, S.; Schwartz, D.; Yachnin, T.; Shapira, I.; Gavish, D.; Baruch, R.; Koifman, B.; Kaplan, C.; Steinbruch, S.; Iaina, A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 2000, 35, 1737-1744.
133. Bashour, F. A.; Jones, E.; Edmonson, R. Cardiac arrhythmias in acute myocardial infarction. II. Incidence of the common arrhythmias with special reference to ventricular tachycardia. Dis. Chest 1967, 51, 520-529.
134. Yesil, M. Management of arrhythmias during transportation in patients with acute myocardial infarction. Anadolu. Kardiyol. Derg. 2007, 7(Suppl. 1), 85-87.
135. Connolly, S. J. Meta-analysis of antiarrhythmic drug trials. Am. J. Cardiol. 1999, 84, 90R-93R.
136. Hirata, A.; Minamino, T.; Asanuma, H.; Sanada, S.; Fujita, M.; Tsukamoto, O.; Wakeno, M.; Myoishi, M.; Okada, K.; Koyama, H.; Komamura, K.; Takashima, S.; Shinozaki, Y.; Mori, H.; Tomoike, H.; Hori, M.; Kitakaze, M. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther. 2005, 19, 33-40.
137. Yue, Y.; Qu, Y.; Boutjdir, M. Protective role of protein kinase C epsilon activation in ischemia-reperfusion arrhythmia. Biochem. Biophys. Res. Commun. 2006, 349, 432-438.
138. Rafiee, P.; Shi, Y.; Su, J.; Pritchard, K. A., Jr.; Tweddell, J. S.; Baker, J. E. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res. Cardiol. 2005, 100, 187-197.
139. Hanlon, P. R.; Fu, P.; Wright, G. L.; Steenbergen, C.; Arcasoy, M. O.; Murphy, E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005, 19, 1323-1325.
140. Oyama, J.; Frantz, S.; Blais Jr, C. Jr.; Kelly, R. A.; Bourcier, T. Nitric oxide, cell death, and heart failure. Heart Fail. Rev. 2002, 7, 327-334.
141. Bristow, M. R. beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101, 558-569.
142. Sabbah, H. N.; Sharov, V. G.; Gupta, R. C.; Todor, A.; Singh, V.; Goldstein, S. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J. Am. Coll. Cardiol. 2000, 36, 1698-1705.
143. Chandrashekhar, Y.; Sen, S.; Anway, R.; Shuros, A.; Anand, I. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J. Am. Coll. Cardiol. 2004, 43, 295-301.
144. Parsa, C. J.; Matsumoto, A.; Kim, J.; Riel, R. U.; Pascal, L. S.; Walton, G. B.; Thompson, R. B.; Petrofski, J. A.; Annex, B. H.; Stamler, J. S.; Koch, W. J. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 2003, 112, 999-1007.
145. Mullonkal, C. J.; Toledo-Pereyra, L. H. Akt in ischemia and reperfusion. J. Invest. Surg. 2007, 20, 195-203.
146. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell 1997, 91, 231-241.
147. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282, 1318-1321.
148. Tramontano, A. F.; Muniyappa, R.; Black, A. D.; Blendea, M. C.; Cohen, I.; Deng, L.; Sowers, J. R.; Cutaia, M. V.; El-Sherif, N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun. 2003, 308, 990-994.
149. Burger, D.; Lei, M.; Geoghegan-Morphet, N.; Lu, X.; Xenocostas, A.; Feng, Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 2006, 72, 51-59.
150. Bullard, A. J.; Govewalla, P.; Yellon, D. M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 2005, 100, 397-403.
151. Fu, P.; Arcasoy, M. O. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem. Biophys. Res. Commun. 2007, 354, 372-378.
152. Clancy, R. M.; Leszczynska-Piziak, J.; Abramson, S. B. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J. Clin. Invest. 1992, 90, 1116-1121.
153. Dodd, F.; Limoges, M.; Boudreau, R. T.; Rowden, G.; Murphy, P. R.; Too, C. K. L-arginine inhibits apoptosis via a NO-dependent mechanism in Nb2 lymphoma cells. J. Cell. Biochem. 2000, 77, 624-634.
154. Kim, Y. M.; Kim, T. H.; Chung, H. T.; Talanian, R. V.; Yin, X. M.; Billiar, T. R. Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 2000, 32, 770-778.
155. Razavi, H. M.; Hamilton, J. A.; Feng, Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol. Ther. 2005, 106, 147-162.
156. Beleslin-Cokic, B. B.; Cokic, V. P.; Yu, X.; Weksler, B. B.; Schechter, A. N.; Noguchi, C. T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004, 104, 2073-2080.
157. Juhaszova, M.; Zorov, D. B.; Kim, S. H.; Pepe, S.; Fu, Q.; Fishbein, K. W.; Ziman, B. D.; Wang, S.; Ytrehus, K.; Antos, C. L.; Olson, E. N.; Sollott, S. J. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. 2004, 113, 1535-1549.
158. Kim, K. H.; Oudit, G. Y.; Backx, P. H. Erythropoietin Protects against Doxorubicin-Induced Cardiomyopathy Via a Pi3k-Dependent Pathway. J. Pharmacol. Exp. Ther. 2008, 324, 160-169.
159. Chen, R. W.; Chuang, D. M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 1999, 274, 6039-6042.
160. Nishihara, M.; Miura, T.; Miki, T.; Sakamoto, J.; Tanno, M.; Kobayashi, H.; Ikeda, Y.; Ohori, K.; Takahashi, A.; Shimamoto, K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H748-H755.
161. Nakatani, K.; Horinouchi, J.; Yabu, Y.; Wada, H.; Nobori, T. Expression of endothelial nitric oxide synthase is induced by estrogen with glycogen synthase 3beta phosphorylation in MCF-7 cells. Oncol. Rep. 2004, 12, 833-836.
162. Kajstura, J.; Cheng, W.; Reiss, K.; Clark, W. A.; Sonnenblick, E. H.; Krajewski, S.; Reed, J. C.; Olivetti, G.; Anversa, P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab. Invest. 1996, 74, 86-107.
163. Romson, J. L.; Hook, B. G.; Kunkel, S. L.; Abrams, G. D.; Schork, M. A.; Lucchesi, B. R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983, 67, 1016-1023.
164. Frangogiannis, N. G.; Smith, C. W.; Entman, M. L. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002, 53, 31-47.
165. Wilson, E. M.; Spinale, F. G. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann. Med. 2001, 33, 623-634.
166. Holmes, J. W.; Borg, T. K.; Covell, J. W. Structure and mechanics of healing myocardial infarcts. Annu. Rev. Biomed. Eng. 2005, 7, 223-253.
167. Bhatia, G. S.; Lip, G. Y. Atrial fibrillation post-myocardial infarction: frequency, consequences, and management. Curr. Heart Fail. Rep. 2004, 1, 149-155.
168. Miller, R. R.; Olson, H. G.; Vismara, L. A.; Bogren, H. G.; Amsterdam, E. A.; Mason, D. T. Pump dysfunction after myocardial infarction: importance of location, extent and pattern of abnormal left ventricular segmental contraction. Am. J. Cardiol. 1976, 37, 340-344.
169. Kirlin, P. C.; Romson, J. L.; Pitt, B.; Abrams, G. D.; Schork, M. A.; Lucchesi, B. R. Ibuprofen-mediated infarct size reduction: effects on regional myocardial function in canine myocardial infarction in canine myocardial infarction. Am. J. Cardiol. 1982, 50, 849-856.
170. Fiordaliso, F.; Chimenti, S.; Staszewsky, L.; Bai, A.; Carlo, E.; Cuccovillo, I.; Doni, M.; Mengozzi, M.; Tonelli, R.; Ghezzi, P.; Coleman, T.; Brines, M.; Cerami, A.; Latini, R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. USA 2005, 102, 2046-2051.
171. Hale, S. L.; Sesti, C.; Kloner, R. A. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 2005, 46, 211-215.
172. Miki, T.; Miura, T.; Tanno, M.; Nishihara, M.; Naitoh, K.; Sato, T.; Takahashi, A.; Shimamoto, K. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res. Cardiol. 2007, 102, 163-170.
173. Miki, T.; Miura, T.; Yano, T.; Takahashi, A.; Sakamoto, J.; Tanno, M.; Kobayashi, H.; Ikeda, Y.; Nishihara, M.; Naitoh, K.; Ohori, K.; Shimamoto, K. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J. Pharmacol. Exp. Ther. 2006, 317, 68-75.
174. Xu, B.; Dong, G. H.; Liu, H.; Wang, Y. Q.; Wu, H. W.; Jing, H. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann. Clin. Lab. Sci. 2005, 35, 161-168.
175. Yang, C. W.; Li, C.; Jung, J. Y.; Shin, S. J.; Choi, B. S.; Lim, S. W.; Sun, B. K.; Kim, Y. S.; Kim, J.; Chang, Y. S.; Bang, B. K. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003, 17, 1754-1755.
176. Shi, Y.; Rafiee, P.; Su, J.; Pritchard, K. A., Jr.; Tweddell, J. S.; Baker, J. E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res. Cardiol. 2004, 99, 173-82.
177. Spinale, F. G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 2002, 90, 520-530.
178. Spinale, F. G.; Gunasinghe, H.; Sprunger, P. D.; Baskin, J. M.; Bradham, W. C. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J. Card. Fail. 2002, 8, S332-S338.
179. Frohlich, E. D. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 1999, 34, 782-789.
180. Chan, C. Y.; Chen, Y. S.; Lee, H. H.; Huang, H. S.; Lai, Y. L.; Chen, C. F.; Ma, M. C. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci. 2007, 81, 717-723.
181. National Kidney Foundation Dialysis Outcomes Quality Initiative. NKFDOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am. J. Kidney Dis. 1997, 30, S192-S240.
182. Besarab, A.; Bolton, W. K.; Browne, J. K.; Egrie, J. C.; Nissenson, A. R.; Okamoto, D. M.; Schwab, S. J.; Goodkin, D. A. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998, 339, 584-590.
183. Bohlius, J.; Wilson, J.; Seidenfeld, J.; Piper, M.; Schwarzer, G.; Sandercock, J.; Trelle, S.; Weingart, O.; Bayliss, S.; Djulbegovic, B.; Bennett, C. L.; Langensiepen, S.; Hyde, C.; Engert, A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006, 98, 708-714.
184. Yasuda, Y.; Fujita, Y.; Matsuo, T.; Koinuma, S.; Hara, S.; Tazaki, A.; Onozaki, M.; Hashimoto, M.; Musha, T.; Ogawa, K.; Fujita, H.; Nakamura, Y.; Shiozaki, H.; Utsumi, H. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003, 24, 1021-109.
185. Lipsic, E.; van der Meer, P.; Henning, R. H.; Suurmeijer, A. J.; Boddeus, K. M.; van Veldhuisen, D. J.; van Gilst, W. H.; Schoemaker, R. G. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2004, 44, 473-479.
186. Mudalagiri, N. R.; Mocanu, M. M.; Di Salvo, C.; Kolvekar, S.; Hayward, M.; Yap, J.; Keogh, B.; Yellon, D. M. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br. J. Pharmacol. 2008, 153, 50-56.
187. Brines, M.; Cerami, A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 2006, 70, 246-250.
188. Bohlius, J.; Langensiepen, S.; Schwarzer, G.; Seidenfeld, J.; Piper, M.; Bennett, C.; Engert, A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J. Natl. Cancer Inst. 2005, 97, 489-498.
189. Namiuchi, S.; Kagaya, Y.; Ohta, J.; Shiba, N.; Sugi, M.; Oikawa, M.; Kunii, H.; Yamao, H.; Komatsu, N.; Yui, M.; Tada, H.; Sakuma, M.; Watanabe, J.; Ichihara, T.; Shirato, K. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. 2005, 45, 1406-1412.
190. Lipsic, E.; van der Meer, P.; Voors, A. A.; Westenbrink, B. D.; van den Heuvel, A. F.; de Boer, H. C.; van Zonneveld, A. J.; Schoemaker, R. G.; van Gilst, W. H.; Zijlstra, F.; van Veldhuisen, D. J. A single bolus of a longacting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 2006, 20, 135-141.
191. Mancini, D. M.; Katz, S. D.; Lang, C. C.; LaManca, J.; Hudaihed, A.; Androne, A. S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107, 294-299.
192. Wisniacki, N. Is anaemia a cause or a consequence of heart failure in the elderly? Heart 2001, 85, 4.
193. Silverberg, D. S.; Wexler, D.; Sheps, D.; Blum, M.; Keren, G.; Baruch, R.; Schwartz, D.; Yachnin, T.; Steinbruch, S.; Shapira, I.; Laniado, S.; Iaina, A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 2001, 37, 1775-1780.
194. Chen, X.; Chen, Y.; Bi, Y.; Fu, N.; Shan, C.; Wang, S.; Aslam, S.; Wang, P. W.; Xu, J. Preventive cardioprotection of erythropoietin against doxorubicininduced cardiomyopathy. Cardiovasc. Drugs Ther. 2007, 21, 367-374.